Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company, announced its financial results for the fourth quarter and full year ended December 31, 2025, highlighting significant progress in its clinical trials and a robust financial position. The company reported cash, cash equivalents, and marketable securities totaling $360 million, a substantial increase from $196.8 million in the previous year, providing a cash runway into 2028. The report included positive topline data from the Phase 2 HORIZON trial of MZE829, which demonstrated a clinically meaningful reduction in proteinuria among patients with APOL1-mediated kidney disease. The results showed a 35.6% mean reduction in urinary albumin-to-creatinine ratio (uACR) at week 12, with 50% of patients achieving over a 30% reduction. Additionally, Maze announced the appointment of Neil Kumar, Ph.D., founder and CEO of BridgeBio Pharma, to its Board of Directors, enhancing the company's leadership with his extensive experience in the biopharmaceutical sector. The company is also set to initiate two Phase 2 trials for MZE782 in phenylketonuria (PKU) and chronic kidney disease (CKD) in 2026, further expanding its clinical pipeline. Overall, Maze's strong financial position and promising clinical data position it well for future growth and development.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.